Patents for A61P 35 - Antineoplastic agents (221,099)
04/2005
04/21/2005WO2005035586A1 Fused protein composition
04/21/2005WO2005035582A1 Composition of antibody capable of specifically binding ccr4
04/21/2005WO2005035581A1 COMPOSITION OF ANTIBODY CAPABLE OF SPECIFICALLY BINDING HUMAN VEGF RECEPTOR Flt-1
04/21/2005WO2005035579A1 A method for the treatment of maligant diseases by inhibiting nucleolin
04/21/2005WO2005035578A1 Antibody composition specifically binding to ganglioside gm2
04/21/2005WO2005035577A1 Antibody composition specifically binding to ganglioside gd3
04/21/2005WO2005035574A1 IgM HIGH CONCENTRATION STABILIZED SOLUTION
04/21/2005WO2005035571A1 Novel glycoprotein and medicinal composition containing the same
04/21/2005WO2005035561A1 Igf-i responsive gene and use thereof
04/21/2005WO2005035548A1 The moduilation of hyaluronan synthesis and degradation in the treatment of disease
04/21/2005WO2005035546A1 Peptide nucleic acid conjugates and uses thereof
04/21/2005WO2005035536A1 Novel xanthone derivative, process for producing the same and pharmaceutical composition containing the same
04/21/2005WO2005035524A1 Pyrrolidinyl urea derivatives as angiogensis inhibitors
04/21/2005WO2005035512A1 Thiadiazoline derivatives
04/21/2005WO2005035503A1 Novel isoquinoline derivative
04/21/2005WO2005035004A1 COMPOSITION FOR INHIBITING FUNCTION OF HUMAN Flt3
04/21/2005WO2005035003A2 Compositions and methods for increasing drug efficiency
04/21/2005WO2005034994A1 Remedy for solid tumor
04/21/2005WO2005034984A1 Cd44 splice variant in diagnosis and therapy of intestinal cancer
04/21/2005WO2005034963A1 USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER
04/21/2005WO2005034959A1 USE OF 2-METHYLENE-19-NOR-20(S)-1a,25-DIHYDROXYVITAMIN D3 TO INCREASE THE LIFE EXPECTANCY OF HUMAN BEINGS
04/21/2005WO2005034953A1 Angiogenesis inhibitor
04/21/2005WO2005034950A1 Pyridothiophene compounds
04/21/2005WO2005034944A1 Combinations of indole compounds and alkylating agents for the treatment of cancer
04/21/2005WO2005034935A1 Use of organoarsenic or organoantimony derivatives for their anticancer properties
04/21/2005WO2005034934A1 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir)
04/21/2005WO2005016970A3 Fully human antibodies directed against the human insulin-like growth factor-1 receptor
04/21/2005WO2005012327A3 Nucleotide phosphoramidates as anticancer agents
04/21/2005WO2005010047A3 Antiangiogenic compounds, pharmaceutical composition containing said compounds and the use thereof
04/21/2005WO2005003776A3 In vitro methods for detecting renal cancer
04/21/2005WO2004111019A3 Protective groups cleavable by serumal albumins
04/21/2005WO2004108142A3 Inhibitors of tip-1 for treatment tissue damage
04/21/2005WO2004105678A3 Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions
04/21/2005WO2004080398A3 1-amino 1h-imidazoquinolines
04/21/2005WO2004069992A3 Oligomeric compounds for the modulation of ras expression
04/21/2005WO2004045490A3 Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof
04/21/2005WO2004026863A8 Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
04/21/2005WO2004005313A3 Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
04/21/2005WO2002099053A3 Slc22as as modifiers of the p53 pathway and methods of use
04/21/2005WO2002092842A3 Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
04/21/2005WO2002092841A3 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
04/21/2005US20050085639 Circulation disorders; antiproliferative agents; hypotensive agents; cardiovascular disorders; antiischemic agents; kidney disorders; atherosclerosis; restenosis; antiinflammatory agents; respiratory system disorders; angiogenesis inhibitors; anticancer agents; antiulcer agents
04/21/2005US20050085637 Pyrimidine compounds
04/21/2005US20050085541 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
04/21/2005US20050085538 Administering strylacrylonitrile compound; antiproliferative agents; anticancer agents
04/21/2005US20050085531 Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
04/21/2005US20050085519 Controlling cell differentiation, cell proliferation; anticancer agents
04/21/2005US20050085515 Active compounds with carbamic acid for diseases such as cancer, leukemia, atheriosclerosis, alzheimers disease or arthritis
04/21/2005US20050085513 Baccatin III analog conjugated to cell binding agent such as monoclonal antibody through a link from the oxygen atom at the C-7 position; treating cancer, rheumatoid arthritis, transplant rejection, viral and parasite infections
04/21/2005US20050085509 KInase inhibitors; antiarthritic agents; autoimmune diseases; sepsis; cachexia; Alzheimer's disease; antihistamines; thrombosis; glomerulonephritis; inflammatory bowel disorders; crohn's disese; multiple sclerosis; antitumor agents; skin disorders
04/21/2005US20050085503 used for detecting diseases where N-acetylated alpha -linked acidic dipeptidase (NAALADase) levels are altered, effecting neuronal activity, effecting TGF- beta activity, inhibiting angiogenesis, and treating glutamate abnormalities, cancer, pain
04/21/2005US20050085490 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
04/21/2005US20050085484 Anticancer agents, particluarly mammary glands, rectums; endometriosis;
04/21/2005US20050085472 Pyrazolo pyrimidine derivatives and methods of use thereof
04/21/2005US20050085471 Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents
04/21/2005US20050085465 Quinazoline compounds
04/21/2005US20050085460 useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease
04/21/2005US20050085448 Viricides against herpes virus; autoimmune disease; antitumor agents
04/21/2005US20050085447 Osteoarthritis; rheumatic disorders ; psoriasis; anklosing spondylitis; atherosclerosis; inflammatory bowel disorders; multiple sclerosis; congestive heart failure; vision defects; chronic obstructive pulmonary disease; asthma; oral diseases; psoriasis; cancer
04/21/2005US20050085433 Cellular vaccines comprising adjuvants
04/21/2005US20050085416 Stabilized albumin, fatty acid complex; anticancer agents; bactericides
04/21/2005US20050084966 Methods for inducing the differentiation of blood monocytes into functional dendritic cells
04/21/2005US20050084936 Human regulatory proteins
04/21/2005US20050084897 DNA encoding human vanilloid receptor VR3
04/21/2005US20050084873 Polypeptide compounds for inhibiting angiogenesis and tumor growth
04/21/2005US20050084489 Synergistic administration of Vitaxin, a FAB fragment, or a competitive binding antibody for binding integrin alpha V beta 3 with the enzyme inhibitor; antiinflammatory, anticarcinogenic agents; autoimmune and metabolic bone disorders
04/21/2005US20050084486 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
04/21/2005US20050084482 As an antiinflammatory agent for gastrointestinal inflammation involved with inflammatory bowel disease or irritable bowel syndrome
04/21/2005US20050084463 Antiinflammatory, antiarthritic agents, analgesics for pain caused by diabetic assoicated conditions, pneumoconiosis, angina, menstruation or cancer
04/21/2005CA2578473A1 Peptide nucleic acid conjugates and uses thereof
04/21/2005CA2548787A1 Antibody composition specifically binding to ganglioside gm2
04/21/2005CA2546730A1 A method for the treatment of malignant diseases by inhibiting nucleolin
04/21/2005CA2542608A1 Igf-i responsive gene and use thereof
04/21/2005CA2542099A1 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
04/21/2005CA2542046A1 Fused protein composition
04/21/2005CA2542037A1 Composition of antibody capable of specifically binding ccr4
04/21/2005CA2542034A1 Thiadiazoline derivatives
04/21/2005CA2541438A1 The modulation of hyaluronan synthesis and degradation in the treatment of disease
04/21/2005CA2540868A1 Pyrrolidinyl urea derivatives as angiogenesis inhibitors
04/21/2005CA2540051A1 Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase the life expectancy of human beings
04/21/2005CA2539449A1 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir)
04/21/2005CA2537473A1 Cytokine involved in epithelial-mesenchymal transition
04/20/2005EP1524273A1 Process for the preparation of trans- or cis-diammoniumdichlorodihydroxyplatinum(IV) salts and derivatives and their use for the preparation of pharmaceutical active agents
04/20/2005EP1524262A1 Inhibitors of histone deacetylase
04/20/2005EP1523991A1 Anti-cancer vaccine
04/20/2005EP1523990A1 Cellular vesicles denoted as 'exosomes', their preparation and use in the stimulation of an immune response
04/20/2005EP1523989A1 Anti cancer vaccine derived from autologous plasma or leucocytes
04/20/2005EP1523988A1 A composition containing radix codonopsis pilosulae and radix astragali and hedysari, method of producing it and use thereof
04/20/2005EP1523985A1 Strontium agent and method for treating cancer
04/20/2005EP1523984A1 Pharmaceutical composition comprising oxoplatin, salts and derivatives thereof
04/20/2005EP1523982A2 Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
04/20/2005EP1523577A2 Method for diagnosis of intestinal-type gastric tumors
04/20/2005EP1523556A1 Methods of treating conditions associated with an edg-1 receptor
04/20/2005EP1523493A1 Novel tubulysin analogues
04/20/2005EP1523488A1 Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
04/20/2005EP1523485A1 3-furanyl analogs of toxoflavine as kinase inhibitors
04/20/2005EP1523484A2 3-phenyl analogs of toxoflavine as kinase inhibitors
04/20/2005EP1523481A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
04/20/2005EP1523480A2 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use
04/20/2005EP1523473A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments